Do LeMaitre Vascular's (NASDAQ:LMAT) Earnings Warrant Your Attention?
Do LeMaitre Vascular's (NASDAQ:LMAT) Earnings Warrant Your Attention?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. But as Peter Lynch said in One Up On Wall Street, 'Long shots almost never pay off.' A loss-making company is yet to prove itself with profit, and eventually the inflow of external capital may dry up.
对初学者而言,买入一家向投资者讲述良好故事的公司(即使目前没有收入和利润记录)可能似乎是个好主意(以及令人兴奋的前景)。但正如彼得·林奇在《华尔街胜经》中所说,“冷门股票几乎从来不会有好结果。” 没有经常盈利的公司尚未通过盈利证明自己,最终外部资本的流入可能会枯竭。
Despite being in the age of tech-stock blue-sky investing, many investors still adopt a more traditional strategy; buying shares in profitable companies like LeMaitre Vascular (NASDAQ:LMAT). Now this is not to say that the company presents the best investment opportunity around, but profitability is a key component to success in business.
尽管处于科技股蓝天投资时代,但许多投资者仍采用更传统的策略,即购买像勒梅特微管医疗(NASDAQ:LMAT)这样有利润的公司的股票。当然,这并不是说该公司提供了最佳的投资机会,但盈利能力是业务成功的关键组成部分。
How Quickly Is LeMaitre Vascular Increasing Earnings Per Share?
勒梅特微管医疗的每股收益增长速度有多快?
Generally, companies experiencing growth in earnings per share (EPS) should see similar trends in share price. That makes EPS growth an attractive quality for any company. LeMaitre Vascular managed to grow EPS by 8.7% per year, over three years. That's a good rate of growth, if it can be sustained.
通常,每股收益(EPS)增长的公司应该看到相似的股价趋势。这使得EPS的增长成为任何公司的有吸引力的品质。勒梅特微管医疗在三年内成功实现了每年8.7%的EPS增长率。如果能够持续下去,这是一个不错的增长率。
It's often helpful to take a look at earnings before interest and tax (EBIT) margins, as well as revenue growth, to get another take on the quality of the company's growth. The good news is that LeMaitre Vascular is growing revenues, and EBIT margins improved by 2.6 percentage points to 20%, over the last year. That's great to see, on both counts.
经常查看利息和税前利润(EBIT)利润率和营收增长,以了解公司增长质量的另一种方式通常很有帮助。好消息是,勒梅特微管医疗正在增长营收,并且过去一年EBIT利润率提高了2.6个百分点至20%。这两点都很棒。
The chart below shows how the company's bottom and top lines have progressed over time. For finer detail, click on the image.
下图显示了该公司底线和顶线随着时间的推移而发展的情况。点击图片以获取更精细的详细信息。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240713/0-5ecc41ae52875dc74b0630a6da7ab896-0-d8b7664591fa15abc60fb5a8c5993e16.png/big)
In investing, as in life, the future matters more than the past. So why not check out this free interactive visualization of LeMaitre Vascular's forecast profits?
在投资和生活中,未来比过去更重要。那么,为什么不查看勒梅特微管医疗的预测利润的免费交互式可视化呢?
Are LeMaitre Vascular Insiders Aligned With All Shareholders?
勒梅特微管医疗的内部人是否与所有股东保持一致?
It should give investors a sense of security owning shares in a company if insiders also own shares, creating a close alignment their interests. Shareholders will be pleased by the fact that insiders own LeMaitre Vascular shares worth a considerable sum. Notably, they have an enviable stake in the company, worth US$172m. Investors will appreciate management having this amount of skin in the game as it shows their commitment to the company's future.
如果内部人也拥有股份,从而实现利益的密切对齐,则拥有公司股份的投资者会感到安全。股东将高兴地发现内部人拥有勒梅特微管医疗股票价值不菲的股份。值得注意的是,他们在公司中拥有令人羡慕的股份,价值1.72亿美元。投资者会欣赏管理层拥有这笔投资,因为这表明了他们对公司未来的承诺。
It's good to see that insiders are invested in the company, but are remuneration levels reasonable? Well, based on the CEO pay, you'd argue that they are indeed. The median total compensation for CEOs of companies similar in size to LeMaitre Vascular, with market caps between US$1.0b and US$3.2b, is around US$5.6m.
虽然内部人投资公司是好事,但薪酬水平合理吗?有了CEO的薪酬,你会认为他们确实是。市值在10亿美元至32亿美元之间的类似规模公司的CEO的中位数总薪酬大约为560万美元。
The CEO of LeMaitre Vascular only received US$2.2m in total compensation for the year ending December 2023. First impressions seem to indicate a compensation policy that is favourable to shareholders. CEO remuneration levels are not the most important metric for investors, but when the pay is modest, that does support enhanced alignment between the CEO and the ordinary shareholders. It can also be a sign of good governance, more generally.
勒梅特微管医疗公司的CEO在截至2023年12月的一年中仅收到220万美元的总薪酬。第一印象似乎表明报酬政策对股东非常有利。CEO薪酬水平不是投资者最重要的衡量指标,但当薪酬较低时,这支持CEO和普通股东之间的强化对齐。通常也是良好治理的标志。
Does LeMaitre Vascular Deserve A Spot On Your Watchlist?
勒梅特微管医疗是否值得列入您的自选股列表?
One positive for LeMaitre Vascular is that it is growing EPS. That's nice to see. Earnings growth might be the main attraction for LeMaitre Vascular, but the fun does not stop there. With company insiders aligning themselves considerably with the company's success and modest CEO compensation, there's no arguments that this is a stock worth looking into. It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with LeMaitre Vascular , and understanding it should be part of your investment process.
勒梅特微管医疗的一个优势是它正在增长每股收益。这很好。虽然盈利增长可能是勒梅特微管医疗最具吸引力的因素,但乐趣并不止于此。随着公司内部人士将自己与公司的成功紧密结合,并获得适度的CEO薪酬,毫无疑问,这是一支值得投资的股票。当然,仍然需要考虑投资风险的存在。我们已经找到勒梅特微管医疗的一个警告信号,理解它应该是您投资过程的一部分。
Although LeMaitre Vascular certainly looks good, it may appeal to more investors if insiders were buying up shares. If you like to see companies with more skin in the game, then check out this handpicked selection of companies that not only boast of strong growth but have strong insider backing.
尽管勒梅特微管医疗看起来非常不错,但如果内部人正在购买股票,则可能吸引更多投资者。如果您希望看到更多内部人支持的公司,那么请查看这些手工精选的公司,这些公司不仅拥有强大的增长,而且有强大的内部人支持。
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
请注意,本文讨论的内部交易是指在相关司法管辖区中报告的交易。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?关注内容?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有反馈? 对内容感到担忧? 请直接与我们联系。 或者,发送电子邮件至editorial-team@simplywallst.com。